Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 14/20 | 0.57 |
| ▸ | ERBB2 | P04626 | 14/20 | 0.57 |
| ▸ | ERBB3 | P21860 | 7/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 7/20 | 0.57 |
| ▸ | BRAF | P15056 | 1/20 | 0.50 |
| ▸ | KDR | P35968 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.50 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11584206 | 0.84 | STK39 (0.65) | STK39EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL25917913 | 0.82 | STK39 (0.50) | STK39EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL26218452 | 0.81 | IDH2 (0.50) | KDRMAPK14TNNI3KTLR8TLR7 | |
| SCHEMBL11584161 | 0.81 | STK39 (0.64) | STK39EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL15832050 | 0.81 | L3MBTL1 (0.60) | STK39EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL22874613 | 0.80 | NR3C1 (0.53) | BRAFKDRMAPK14TNNI3KTLR8 | |
| SCHEMBL22874574 | 0.79 | PNLIP (0.55) | STK39EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL10538095 | 0.79 | NPSR1 (0.57) | STK39EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL11121304 | 0.79 | STK39 (0.50) | STK39EGFRERBB2ERBB3ERBB4 | |
| SCHEMBL2747848 | 0.79 | EGFR (0.53) | STK39EGFRERBB2ERBB3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1752457-B1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL (JP) | 2014-03-19 | — | — | EP | disclosed |
| US-8178543-B2 | growth factor receptor tyrosine kinase inhibitor; anticarcinogenic agents; N-{2-[4-({3-chloro-4-[3-(trifluoromethyl)phenoxy]phenyl}amino)-5H-pyrrolo[3,2-d]pyrimidin-5-yl]ethyl}-3-hydroxy-3-methylbutanamide | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20090203717-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-08-13 | — | — | US | disclosed |
| US-7507740-B2 | Fused heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-24 | — | — | US | disclosed |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-01-15 | — | — | US | disclosed |
| US-20070244132-A1 | Fused Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-10-18 | — | — | US | disclosed |
| EP-1752457-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-02-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203717-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | STK39 3014/4885EGFR 68/4885ERBB2 21/4885 |
| US-20070244132-A1 | Fused Heterocyclic Compound | NOX3, ERBB3, CBR3 | STK39 3014/4885EGFR 68/4885ERBB2 21/4885 |
| US-20090029973-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | STK39 3014/4885EGFR 68/4885ERBB2 21/4885 |
| US-20090018335-A1 | FUSED HETEROCYCLIC COMPOUND | NOX3, ERBB3, CBR3 | STK39 3014/4885EGFR 68/4885ERBB2 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.